Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation
| Status: | Terminated |
|---|---|
| Conditions: | Women's Studies |
| Therapuetic Areas: | Reproductive |
| Healthy: | No |
| Age Range: | 21 - 33 |
| Updated: | 11/23/2018 |
| Start Date: | April 2012 |
| End Date: | December 2014 |
A Prospective Comparison of Transcriptional Profiling of Luteal Phase Endometrial Biopsies After Induction of Oocyte Maturation With a Gonadotropin Releasing Hormone (GnRH) Agonist or Human Chorionic Gonadotropins (hCG)
The purpose of this study is to compare gene expression profiles in endometrial biopsies
during the window of implantation after triggers of oocyte maturation using GnRH agonist or
hCG and compared with their natural cycles in order to identify genes that may be
dysregulated in GnRH agonist-triggered cycles.
The investigators also intend to evaluate patients feeling of well being and physical quality
of life after GnRH agonist trigger compared with hCG trigger.
during the window of implantation after triggers of oocyte maturation using GnRH agonist or
hCG and compared with their natural cycles in order to identify genes that may be
dysregulated in GnRH agonist-triggered cycles.
The investigators also intend to evaluate patients feeling of well being and physical quality
of life after GnRH agonist trigger compared with hCG trigger.
Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic complication of controlled ovarian
hyperstimulation (COH) which may result in significant morbidity and rarely mortality as well
as significant financial and psychological distress. The use of a GnRH agonist for induction
of final oocyte maturation in ovarian stimulation cycles utilizing GnRH antagonist for
pituitary suppression has proven to be an effective method of preventing the risk of OHSS
development.
Unfortunately, some studies, but not all, have also reported lower pregnancy rates in these
cycles as compared to cycles using hCG trigger and this has been attributed to possible
impaired endometrial receptivity.
The investigators intend to obtain endometrial biopsies collected from the same subject in a
natural cycle and then a biopsy during either a GnRH agonist or hCG triggered stimulation.
Expression profiles of mRNAs will first be screened using microarray technology. Relative
levels of specific mRNAs that display altered expression in the GnRH-triggered samples, as
assayed by microarray, will then be confirmed by real-time, quantitative reverse
transcription/polymerase chain reaction (Q-PCR). The investigators shall also evaluate
patients feeling of well being and physical quality of life after GnRH agonist trigger
compared with hCG trigger.
hyperstimulation (COH) which may result in significant morbidity and rarely mortality as well
as significant financial and psychological distress. The use of a GnRH agonist for induction
of final oocyte maturation in ovarian stimulation cycles utilizing GnRH antagonist for
pituitary suppression has proven to be an effective method of preventing the risk of OHSS
development.
Unfortunately, some studies, but not all, have also reported lower pregnancy rates in these
cycles as compared to cycles using hCG trigger and this has been attributed to possible
impaired endometrial receptivity.
The investigators intend to obtain endometrial biopsies collected from the same subject in a
natural cycle and then a biopsy during either a GnRH agonist or hCG triggered stimulation.
Expression profiles of mRNAs will first be screened using microarray technology. Relative
levels of specific mRNAs that display altered expression in the GnRH-triggered samples, as
assayed by microarray, will then be confirmed by real-time, quantitative reverse
transcription/polymerase chain reaction (Q-PCR). The investigators shall also evaluate
patients feeling of well being and physical quality of life after GnRH agonist trigger
compared with hCG trigger.
Inclusion Criteria:
- Oocyte donors
- Ages between 21 and 33
- Normal baseline serum FSH < 10mIU/mL
Exclusion Criteria:
- Hypothalamic dysfunction
- Smokers
- Baseline serum FSH ≥ 10mIU/mL
We found this trial at
1
site
Click here to add this to my saved trials
